Akorn, Inc. (AKRX)
AKRX Price and Sentiment
AKRX Latest news
Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%
2021-02-11 09:10LAKE FOREST, Ill., Feb. 11, 2021 /PRNewswire/ -- Akorn Operating Company LLC (Akorn), a leading specialty pharmaceutical company, announced that it received approval of its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Loteprednol Etabonate...
Akorn Receives Court Approval of Sale to Lenders
2020-09-02 08:42LAKE FOREST, Ill., Sept. 2, 2020 /PRNewswire/ -- Akorn, Inc.
Akorn to Use Voluntary Chapter 11 Process to Position Business for Long-Term Success
2020-05-20 23:52LAKE FOREST, Ill., May 20, 2020 /PRNewswire/ -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company ("Akorn" or the "Company"), today announced that the Company and its U.S. subsidiaries filed for voluntary protection under Chapter 11 ("Chapter 11") of the U.S....
5 Small-Cap Stocks Outpacing the Broader Market in 2019
2019-11-11 07:03Despite the slow pace of movement of small-cap stock prices, a few stocks within this stable have skyrocketed ahead of the large-cap-centric indexes this year.
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15%
2019-08-26 13:35LAKE FOREST, Ill., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Azelastine Hydrochloride Nasal Spray, 0.15%. The product is manufactured at Akorn’s Amityville, New York manufacturing facility.
Analysts Estimate Akorn (AKRX) to Report a Decline in Earnings: What to Look Out for
2019-07-25 10:33Akorn (AKRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Generics maker Akorn receives warning letter from the FDA relating to NJ facility
2019-06-25 07:44Generics company Akorn Inc. said Tuesday it has received a warnings letter from the U.S. Food and Drug Administration, relating to the inspection of a facility in New Jersey in July and August of 2018.
Akorn (AKRX) Reports Q1 Loss, Tops Revenue Estimates
2019-05-07 08:35Akorn (AKRX) delivered earnings and revenue surprises of 28.57% and 8.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Akorn Stock Rose as Much as 14.4% Today
2019-04-22 12:58The embattled generic-pharmaceutical manufacturer earned two new product approvals.